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Abstract
Objectives—This study examined PSA screening interval of black and white men aged 65 or older
and its association with prostate cancer stage at diagnosis.
Methods—SEER-Medicare data were examined for 18,067 black and white men diagnosed with
prostate cancer between 1994 and 2002. Logistic regression was used to assess the association
between race, PSA screening interval, and stage at diagnosis. Analysis also controlled for age, marital
status, comorbidity, diagnosis year, geographic region, income, and receipt of surgery.
Results—Compared to whites, blacks diagnosed with prostate cancer were more likely to have had
a longer PSA screening interval prior to diagnosis, including a greater likelihood of no pre-diagnosis
use of PSA screening. Controlling for PSA screening interval was associated with a reduction in
blacks’ relative odds of being diagnosed with advanced (stage III or IV) prostate cancer, to a point
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that the stage at diagnosis was not statistically different from that of whites (OR=1.12, 95% CI=0.98–
1.29). Longer intra-PSA intervals were systematically associated with greater odds of diagnosis with
advanced disease.
Conclusions—More frequent or systematic PSA screening may be a pathway to reducing racial
differences in prostate cancer stage at diagnosis, and, by extension, mortality.
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Introduction
Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in American men,
with approximately 192,000 new cases and 27,000 prostate cancer deaths in 2009 [1]. Black
men suffer a disproportionate burden from the disease, with 1.6 times greater incidence and
2.4 times greater mortality than that of white [2]. Investigators have examined clinical and
sociodemographic factors, access to and utilization of early detection and treatment, and tumor
characteristics as possible explanations for the tremendous disparity in prostate cancer
mortality; [3–8] however, the underlying causes of the racial disparity remain poorly
understood. Biological factors, including genetics and dietary differences, may play a role in
the racial disparity [9–12]. Until there is more evidence of the relative impact of these factors,
examining the use of early detection and its effectiveness remains critical.
Stage at diagnosis is strongly associated with survival [13,14], and early detection has proved
successful in reducing mortality from other cancers, such as breast, colorectal, and cervical
[15–17]. The prostate-specific antigen (PSA) test is commonly used for screening for prostate
cancer and has contributed to a dramatic increase in disease detection [18]. Observational
studies have shown a reduction in prostate cancer-specific mortality in men who undergo PSA
testing [19–21], but recent results from two large randomized controlled trials have not
consistently supported the role of PSA in reducing mortality. The Prostate, Lung, Colorectal,
and Ovarian (PLCO) Cancer Screening Trial included over 75,000 American men with 7–10
years of follow-up and found no significant difference in mortality rates [22]. The European
Randomized Study of Screening for Prostate Cancer included over 165,000 men with an
average of 9 years of follow-up, and resulted in a 20% decrease in mortality, but at the cost of
increased risk of overdiagnosis [23].
However, neither of these studies included a sufficient number of black men to analyze
differences by race, so any benefit of PSA in this population remains unclear. Studies have
found an association between serial PSA screening and a decrease in clinically advanced and
high grade disease [24], stage migration from distant to earlier stages [25,26], and an evolution
toward earlier pathologic stage, grade, and PSA outcome [27]. Meanwhile, blacks continue to
be more commonly diagnosed with higher stage and grade tumors than their white counterparts
[28].
Better understanding of racial differences in the use of early detection and the associated stage
at diagnosis may contribute to understanding the racial disparity in prostate cancer mortality.
As a result of differences in clinical and sociodemographic factors and tumor biology between
races, optimal PSA screening interval may differ by race, and this difference may be associated
with the racial disparity in stage at diagnosis. In completed studies of PSA screening interval,
it has been shown that a shorter interval is associated with earlier stage and less severe grade
at diagnosis [29,30]. This study examines PSA screening interval as it is associated with racial
differences in prostate cancer stage at diagnosis among a group of black and white men aged
65 or older.
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Data are from the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked
database, described in detail elsewhere [31]. Briefly, SEER-Medicare is a collaborative effort
between the National Cancer Institute's SEER program and the Medicare program, offering a
comprehensive dataset of cancer diagnosis and treatments as well as other diseases and
conditions that may influence treatment and survival. The eight SEER registries used in this
study represent 11% of the US population.
Each registry collects data on newly diagnosed cases of cancer including histology, grade,
stage, and treatment, as well as patient demographic characteristics, follow-up of vital status,
and cause of death (if applicable). Medicare provides health insurance coverage to
approximately 97% of Americans 65 years of age or older. Medicare data reflect diagnoses
and health services provided to beneficiaries by physicians, hospitals, home health care
agencies, nursing facilities, and hospice programs.
Study population
Data from the SEER-Medicare linked database were examined for black and white men
diagnosed with prostate cancer between 1994 and 2002 from the following eight SEER
registries: Atlanta, Connecticut, Detroit, Rural Georgia, Los Angeles, San Francisco-Oakland,
San Jose, and Seattle-Puget Sound. Men were included if they were aged 65 or older at
diagnosis, had known prostate cancer stage, had no prior or concurrent cancers, no gaps in
Medicare coverage from enrollment to diagnosis, continuous coverage for 3 years prior to
diagnosis, and no HMO coverage from enrollment to diagnosis.
Measurement of variables
The primary study outcome, tumor stage at diagnosis, was obtained from SEER data. Tumor
stage was based on the American Joint Committee on Cancer (AJCC) staging criteria and
classified as early stage (stage 1 or 2) or advanced stage (stage 3 or 4). Histological grade was
classified in the SEER data, based on Gleason score, as well-differentiated (2–4), moderately
differentiated (5–7), poorly differentiated (8–10), or undifferentiated/anaplastic [32]. For the
purposes of this analysis, poorly (n = 4,321) and undifferentiated (n = 72) tumors were
combined into a single category.
Time since last PSA test was ascertained from Medicare claims data using Healthcare Common
Procedure Coding System (HCPCS) codes 84153, 84154, 86316, and G0103 to identify PSA
tests. Only PSA tests occurring greater than 2 months, prior diagnosis month was included in
order to avoid inclusion of repeat PSA tests used as a part of patient diagnostic workup [33].
Patient race (black or white), age (65–69, 70–74, 75–79, 80+), marital status, and year of
diagnosis were also obtained from SEER data. A comorbidity index score was calculated for
each patient using Medicare claims up to 12 months prior to diagnosis date in an algorithm
developed specifically for use with SEER-Medicare data [34]. For cancers diagnosed prior to
1998, surgical procedures were evaluated using SEER site-specific surgery codes 10–29 for
transurethral resection of the prostate (TURP), 30–99 for prostatectomy and 01–06 for biopsy.
Reflecting a coding system change, for diagnosis years 1998 and onward we used SEER
surgery of the primary site codes 10–17 for TURP, and 30–98 for prostatectomy. Zip code-
level aggregate indicators of education and income from the 2000 census were examined as
quartiles based on the analytic sample.
Analysis
Descriptive analyses were performed to assess patient characteristics by race and time interval
since last PSA test. Chi-square tests were used for bivariate comparisons of patient
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characteristics by race. Multivariate logistic regression was used to examine associations
between race, screening interval, and cancer stage at diagnosis. Models were examined
sequentially to assess the baseline racial differences in stage at diagnosis, the differences when
controlling for potential confounders (“fully specified”), and effect of adding screening interval
to the fully specified model. In the baseline model (Table 2, Model 1) SEER site was retained
to control for obvious regional differences, including that a substantial portion of the overall
black sample resided in Detroit, and that population's systematically different use of PSA
compared to black's in other SEER regions. The fully specified model included age at diagnosis,
marital status, diagnosis year, comorbidity score, median household income, and receipt of
surgery/related procedure as covariates. Receipt of surgery was included in regression models
to account for the possibility of tumor upstaging in men who underwent prostatectomy, and
comorbidity was included to control for differential exposure to health care services, including
PSA tests resulting from comorbid or ongoing health conditions.
Multiple sensitivity analyses and model specification tests were conducted. Among them,
interactions between race and screening interval were assessed (and found to be non-
significant). Additional sensitivity analyses were conducted examining asymptomatic and
symptomatic PSAs independently and then all PSAs regardless of corresponding symptoms
or diagnosis. For these analyses, PSA tests were categorized as symptomatic if a diagnosis
code for any lower urinary tract symptoms (LUTS) was included on insurance claims within
30 days prior to 7 days post-PSA claim date, and as asymptomatic if no LUTS were included
on claims within the specified window. All statistical tests were two-sided with a significance
level of 0.05. All analyses were conducted using SAS® Version 9.1 (SAS Institute, Cary, NC).
Results
The analytic sample included 18,067 men (15.8% black and 84.2% white), as presented in
Table 1. The mean age was 74.7 (standard deviation (SD) = 5.9) for blacks and 75.4 (SD =
5.7) for whites. Many men had undergone PSA testing within a year prior to diagnosis, though
whites were more likely to have done so (blacks: 40.4%; whites 46.1%). Blacks were more
likely than whites to have had no PSA tests prior to diagnosis (black: 32.8%, white: 22.1%;
p < 0.001). Screening intervals also varied by cancer stage; men diagnosed with advanced-
stage tumors were more likely to have no PSA tests prior to diagnosis (advanced: 36.9%; early:
19.6%) and less likely to have been tested within a year of diagnosis (advanced: 34.4%; early:
48.6%) than those with early stage tumors (data not shown). Compared to white men, black
men in our sample were less likely to be married and were more likely to live in areas with
lower average education levels and lower median household income (Table 1). Significantly
more black (52.8%) than white (29.6%) men were from the Detroit SEER region, which
included the largest fraction of black men in the study sample. Black men had greater
comorbidity, as reflected by a higher percentage with a comorbidity score of 1 or higher (38.6
vs. 29.6%, p < 0.001). Overall unadjusted rates of early versus advanced stage at diagnosis
were comparable between black and white men. Over 60% of men in the sample had undergone
a surgery-related procedure with 16.9 and 10.8% of white and black men, respectively, having
undergone a prostatectomy.
Several differences were noted between demographic characteristics of blacks and whites
within the same PSA testing intervals (data not shown). Blacks in the 3–12-month interval and
those with no PSA tests prior to diagnosis were younger than their white counterparts. The
percent of whites and blacks in the no PSA testing group declined over time; however,
significantly more whites than blacks with no prior PSA test had been diagnosed prior to 1996
(44.8 vs. 36.7%). Additionally, blacks in all testing intervals were less likely to be married and
resided in zip code areas with higher percentages of less than high school graduates and lower
median household incomes than whites. Examination of clinical characteristics by race and
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PSA screening interval showed that blacks were consistently more likely than whites to have
one or more comorbidities. Among those who had a PSA test prior to prostate cancer diagnosis,
blacks were more likely than whites to have no urinary symptoms at the time of their last PSA
test.
Multivariate logistic regression analysis of cancer stage at diagnosis revealed that blacks had
higher odds of advanced-stage versus early stage cancer at diagnosis than did whites (odds
ratio (OR) = 1.24, 95% CI: 1.13–1.37) than whites (Table 2, Model 1). A more fully specified
model, including multiple confounders, resulted in a non-significant decline in the racial
difference (OR=1.21, 95% CI: 1.06–1.39). Further controlling for PSA screening interval in
this model resulted in a 7% decrease in odds of being diagnosed with advanced-stage cancer
compared to the base model (OR=1.12, 95% CI=0.98–1.29), and the difference between blacks
and whites was no longer statistically significant. The more fully specified model adjusting for
race, screening interval, SEER site, age, marital status, comorbidity score, diagnosis year,
income, and receipt/type of surgery showed an association between screening interval and odds
of advanced-stage cancer that was both persistent and in the hypothesized direction. That is,
greater time since the last PSA was systematically associated with a greater probability of being
diagnosed with advanced disease, while the independent association with race remained non-
significant. Those with no prior history of PSA in their Medicare claims were nearly three
times more likely to be diagnosed with advanced disease than those who had their most recent
PSA one year or less prior to diagnosis. More recent diagnosis years were associated with lower
odds of advanced-stage cancers, as were living in a higher income area and being married.
Discussion
To elucidate factors that may contribute to the tremendous racial disparity in prostate cancer
mortality, this study examined the association between PSA screening interval and stage at
diagnosis in a large sample of older black and white men with prostate cancer. In this
population, overall and race-specific stage at diagnosis are reflective of the overall national
trends in stage at diagnosis. Unadjusted data in this study present equivalent stage groupings
at diagnosis (Stage I/II, Stage III/IV), though national data present black men as having slightly
greater rates of diagnosis with metastatic disease [2]. When controlling for multiple
confounders, black men in this study population were more likely than white men to be
diagnosed with advanced disease. The length of the pre-diagnosis PSA screening interval was
strongly associated with stage at diagnosis, and its inclusion in the analysis was associated with
substantial attenuation in racial differences in stage at diagnosis. Specifically, when controlling
for screening interval, there was no statistical difference between black and white men's stage
at diagnosis. In contrast, the addition of multiple, often-studied covariates (age, marital status,
year of diagnosis, income, comorbidity, surgery/surgery type) was associated with only limited
change in the relationship between race, screening interval, and stage at diagnosis. These
associations suggest that screening interval may be a relevant factor in explaining racial
differences in prostate cancer outcomes, perhaps as a function of the greater number of
treatment options and typically better outcomes associated with early stage diagnosis.
Variation among SEER regions was notable in terms of both PSA screening use and stage at
diagnosis, likely based on regional differences in care patterns. For example, the Detroit SEER
region includes approximately 50% of the black men in our sample, and in this sample the
distribution of screening interval among blacks was similar to the screening interval of whites
residing not only in Detroit but also to whites in the rest of the study sample. These systematic
geographic differences mandated controlling for region in all analyses and point to an area of
opportunity for further, closer study, as the different health care patterns and outcomes could
result from many factors. Among them, it may be that blacks in Detroit span a wider spectrum
of socioeconomic status, which may contrast with other SEER regions such as Connecticut or
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Seattle, in which the smaller black population may be much less diverse such that a higher
screening population is not well represented. There may also be different social norms among
blacks in this region that are associated with greater use of health care in general, and preventive
health care specifically. Alternatively, it may be that there are unique organizational
characteristics or a prevention orientation of a dominant health system in this geographically
small region. Understanding these factors may elucidate a model for other health systems in
other regions to follow.
The effectiveness of PSA screening in terms of reducing prostate cancer mortality remains
controversial;[35,36] however, these findings support the hypothesis that screening interval
plays a role in racial disparities in the stage of disease at diagnosis, so addressing differences
in screening practices may reduce disparities in mortality. Previous work suggests that racial
differences in the use of prostate cancer early detection are a function of differences in
individuals’ usual source of care and associated variation in patient–provider interactions, and
health care systems and processes [37,38]. These studies document substantial differences in
pre-diagnosis prostate cancer screening use among men diagnosed with prostate cancer
depending on the continuity of care and the usual source of care (e.g., private practice, hospital
clinic, community health clinic, emergency room, etc.), and posit that physician biases and
practical constraints that differ by source of regular care may inhibit physicians’ and patients’
ability to inquire beyond the primary issue at hand to preventive health issues and secondary
or more complex issues. Moreover, these differences are likely to vary systematically according
to the systems in place at the care sites that serve as individuals’ usual sources of care. This
study reinforces these earlier findings by demonstrating lower and less frequent use of PSA
screening by blacks compared to whites and racial differences in stage at diagnosis. Substantial
regional variation in pre-diagnosis prostate cancer screening suggests merit in a more extensive
examination of racial differences in prostate cancer incidence and mortality in terms of the
usual source of care, the continuity and quality of physician-patient interaction, differential use
of prostate cancer early detection, and stage and grade at diagnosis.
These study results suggest a pathway to reducing the racial differences in the initial prostate
cancer stage through a decrease in the PSA screening intervals—that is, more and more frequent
use of PSA screening—among black. However, while this study found an association between
screening interval and racial disparities in the stage at diagnosis, it does not fully address racial
differences in cancer aggressiveness, which arguably may be a more important predictor of
prostate cancer outcomes, a point amplified by a recent study by Albain and colleagues
demonstrating the persistence of racial mortality differences among white and black men with
similarly advanced-stage prostate cancer [39]. This study lends insight into racial differences
in screening and stage at diagnosis, but does not address the overall question of whether PSA
screening is effective in reducing prostate cancer mortality among blacks at any screening
interval. With this regard, PSA effectiveness may also differ by race, an association that was
not evaluated by the PLCO and European studies [22,23].
The issue of racial differences in PSA testing compounds the already complex issue of PSA
screening in general, as health care scientists and clinicians continue to examine several
variations of PSA testing, including the distributions of total PSA, free PSA, percent free PSA,
and others. PSA level varies with age and race-ethnicity among American men and may lead
to different thresholds of PSA tests and perhaps different screening intervals [40]. Patients
diagnosed by annual prostate cancer screening appeared more likely to experience an indolent
PSA recurrence and less likely to die of prostate cancer after PSA recurrence compared with
patients referred from the community [41]. A single PSA test taken at or before age 50 is a
very strong predictor of advanced prostate cancer diagnosed up to 25 years later. This suggests
the possibility of using an early PSA test to risk-stratify patients so that men at highest risk are
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the focus of the most intensive screening efforts, an intervention that would need to be tested
in a controlled trial [42].
The use of administrative claims-based data allowed the examination of a substantially larger
population than would be feasible through an interview- or medical records-based study;
however, the health services documented in the data only reflect those that have an associated
procedure code and are reimbursed by Medicare. As such, these data would not capture a PSA
that was provided and not billed for, such as through a free community screening event. Perhaps
more importantly, because digital rectal examinations (DRE) are commonly considered a part
of the regular office visit and not consistently billed for independently, these data do not reliably
reflect its use and so it was excluded from the analysis; however, DRE has not been shown to
prevent cancer-related deaths. This being said, all individuals in this study were enrolled
continuously in Medicare, reflecting at least a stable baseline set of health care resources.
Finally, Medicare did not reimburse for screening PSA prior to the year 2000, and so the
presence of PSA in Medicare claims prior to this point and the validity of associated diagnoses
or symptoms (i.e., such as would differentiate between asymptomatic screening, or
symptomatic testing) are unknown and likely to be variable.
Conclusion
For the general public and medical and public health practitioners, this study's results are
promising and complement prior research demonstrating variation in pre-diagnosis screening
use among differing levels of care continuity and different sources of regular care. Together,
they suggest merit in additional research integrating the study of prostate cancer screening
intervals, care continuity and usual source of care, and stage and grade at diagnosis as they
may differ by race. Biological differences may be contributing to prostate cancer outcomes,
but at least a portion of the racial disparity in prostate cancer mortality may be resolved by
addressing the care systems and care continuity among care providers where black men are
more likely than white men to seek regular care. The association between increasing screening
interval and progressively increased risk of diagnosis with advanced disease informs the
research community regarding appropriate prostate cancer screening interval for all men,
including the prospect of screening recommendations that may differ according to different
personal risk levels.
Compared to other cancers, many aspects of prostate cancer remain an enigma, not the least
of which concerns the appropriate use of screening and early detection, particularly given the
debate surrounding its efficacy. What remains clear is that there is much to learn regarding
both biological and sociological characteristics influencing the etiology of the disease, efficacy
and appropriate use of early detection, and treatment decisions that appropriately balance
maximizing survival while minimizing the risk of unnecessary or excessive treatment risks and
side effects. The extraordinary racial disparities in incidence and especially mortality place a
premium on each new discovery and piece of new information.
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Table 1
Demographic and clinical characteristics by race for men diagnosed with stage 1–4 prostate cancer, SEER-
Medicare 1994–2002
Characteristics n(% of column) pa
Total n = 18,067 White n = 15,219 Black n = 2,848
Months since last PSA <0.001
  3–12 8,164(45.2) 7,013(46.1) 1,151(40.4)
  13–24 3,190(17.7) 2,796(18.4) 394(13.8)
  25–36 1,104(6.1) 953(6.3) 151(5.3)
  37–128 1,317(7.3) 1,099(7.2) 218(7.7)
  No PSA 4,292(23.8) 3,358(22.1) 934(32.8)
Cancer stage 0.999
  Early stage (stage 1–2) 13,734(76.0) 11,569(76.0) 2,165(76.0)
  Advanced stage (stage 3–4) 4,333(24.0) 3,650(24.0) 683(24.0)
Histological grade <0.001
  Well differentiated 218(1.2) 196(1.3) 22(0.8)
  Moderately differentiated 12,896(71.4) 10,948(71.9) 1,948(68.4)
  Poorly differentiated 4,393(24.3) 3,628(23.8) 765(26.9)
  Unknown 560(3.1) 447(2.9) 113(4.0)
Age at diagnosis <0.001
  65–69 2,997(16.6) 2,401(15.8) 596(20.9)
  70–74 6,211(34.4) 5,223(34.3) 988(34.7)
  75–79 4,966(27.5) 4,256(28.0) 710(24.9)
  80+ 3,893(21.5) 3,339(21.9) 554(19.5)
Married <0.001
  Yes 12,431(68.8) 10,903(71.6) 1,528(53.7)
  No 4,617(25.6) 3,499(23.0) 1,118(39.3)
  Unknown 1,019(5.6) 817(5.4) 202(7.1)
Diagnosis year 0.043
  1994 2,687(14.9) 2,306(15.2) 381(13.4)
  1995 2,276(12.6) 1,933(12.7) 343(12.0)
  1996 2,177(12.0) 1,800(11.8) 377(13.2)
  1997 2,124(11.8) 1,761(11.6) 363(12.7)
  1998 1,968(10.9) 1,667(11.0) 301(10.6)
  1999 1,873(10.4) 1,570(10.3) 303(10.6)
  2000 1,784(9.9) 1,496(9.8) 288(10.1)
  2001 1,664(9.2) 1,422(9.3) 242(8.5)
  2002 1,514(8.4) 1,264(8.3) 250(8.8)
SEER site <0.001
  Atlanta 1,507(8.3) 1,084(7.1) 423(14.9)
  Connecticut 3,139(17.4) 2,959(19.4) 180(6.3)
  Detroit 5,475(30.3) 3,971(26.1) 1,504(52.8)
  Los Angeles 2,445(13.5) 2,089(13.7) 356(12.5)
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Characteristics n(% of column) pa
Total n = 18,067 White n = 15,219 Black n = 2,848
  Rural Georgia 95(0.5) 50(0.3) 45(1.6)
  San Francisco 1,564(8.7) 1,329(8.7) 235(8.3)
  San Jose 929(5.1) 899(5.9) 30(1.1)
  Seattle 2,913(16.1) 2,838(18.6) 75(2.6)
Zip code % non-high school graduates <0.001
  0–8.4% 4,311(23.9) 4,228(27.8) 83(2.9)
  8.5–13.6% 4,422(24.5) 4,249(27.9) 173(6.1)
  13.7–21.5% 4,326(23.9) 3,788(24.9) 538(18.9)
  21.6–100% 4,326(23.9) 2,341(15.4) 1,985(69.7)
  Unknown 682(3.8) 613(4.0) 69(2.4)
Zip code median household income <0.001
  ≤$41,302 4,350(24.1) 2,208(14.5) 2,142(75.2)
  $41,303–$51,222 4,351(24.1) 3,994(26.2) 357(12.5)
  $51,223–$64,833 4,340(24.0) 4,125(27.1) 215(7.5)
  $64,834–$200,008 4,344(24.0) 4,279(28.1) 65(2.3)
  Unknown 682(3.8) 613(4.0) 69(2.4)
Comorbidity score <0.001
  0 11,787(65.2) 10,293(67.6) 1,494(52.5)
  1 3,692(20.4) 3,031(19.9) 661(23.2)
  2+ 1,907(10.6) 1,468(9.6) 439(15.4)
  Unknown 681(3.8) 427(2.8) 254(8.9)
Symptoms at last PSA <0.001
  Hematuria/vascular disorders 437(2.4) 355(2.3) 82(2.9)
  Other urinary symptoms (not hematuria) 7,763(43.0) 6,841(45.0) 922(32.4)
  No urinary symptoms 5,575(30.9) 4,665(30.7) 910(32.0)
  No PSA 4,292(23.8) 3,358(22.1) 934(32.8)
Surgery type <0.001
  Exploratory Biopsy 5,419(30.0) 4,573(30.0) 846(29.7)
  TURP 2,820(15.6) 2,319(15.2) 501(17.6)
  Prostatectomy 2,877(15.9) 2,570(16.9) 307(10.8)
Per SEER-Medicare policy, to protect confidentiality, the count of ‘unknowns’ for some variables is not presented
a
p-value comparing characteristics of black and white men obtained from Chi-square test TURP=transurethral resection of the prostate
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